** Shares of Massachusetts-based gene-editing firm Intellia Therapeutics NTLA.O up 8.4% at $11.71
** Company posts Q4 collaboration revenue of $12.9 million, beating analysts' estimates of $8.5 million, according to data compiled by LSEG
** Company's sales was mainly driven by collaboration revenue received under the Regeneron REGN.O agreements to develop gene-editing therapies for neurological and muscular disease
** Brokerage Leerink Partners expects shares to rise in the mid-single digits as company fleshed out details including operating expenses on call; NTLA expects 5%-10% lower operating expenses vs a year ago
** NTLA also expects operating expense below 2024 levels for the next several years as R&D spend sunsets with enrollment completion/trial conclusions in 2026 and beyond
** Company plans to submit a marketing application for a rare genetic disorder therapy, NTLA-2002, in H2 2026 to a potential U.S. launch in 2027
** "NTLA-2002 remains the most underappreciated asset in our coverage universe heading into upcoming pivotal (trial) data," brokerage says
** NTLA fell 61% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。